CRISPR THERAPEUTICS AG (CRSP) FY2026 YTD Q2 P&L / Income Statement

CRISPR THERAPEUTICS AG (CRSP) FY2026 YTD Q2 P&L / Income Statement

Income statement for 2026-01-01 through 2026-06-30. View: Product and service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Total revenue

11,639,000 US dollars

Total operating expenses

259,156,000 US dollars

Loss from operations

negative 247,517,000 US dollars

Total other income, net

35,231,000 US dollars

Net loss before income taxes

negative 212,286,000 US dollars

Provision for income taxes

1,799,000 US dollars

Net loss

negative 214,085,000 US dollars

Collaboration Revenue

11,000,000 US dollars

Grant Revenue

639,000 US dollars

Total operating expenses

259,156,000 US dollars

Chart connections

• Revenue minus operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.